Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: A study on environmental malignant mesothelioma cases from Turkish villages

Pathology and Oncology Research

Volumn 8, Issue 3, 2002, Pages 188-193

  Gümürdülü, Derya ^a   Zeren, E Handan ^a   Cagle, Philip T ^b   Kayaselçuk, Fazilet ^a   Alparslan, Nazan ^c   Kocabaş, Ali ^c   Tuncer, Ilhan ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Department of Biostatistics ^*  (Turkey)

Author keywords

Adenocarcinoma; Environmental malignant mesothelioma; HBME 1; MOC 31; Turkey

Indexed keywords

ANTIBODY; CARCINOEMBRYONIC ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; KERATIN; PERIODIC ACID; PROTEIN HBME 1; PROTEIN MOC 31; TUMOR MARKER; UNCLASSIFIED DRUG; HBME 1 ANTIGEN; HBME-1 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADENOCARCINOMA; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENVIRONMENTAL FACTOR; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PERIODIC ACID SCHIFF STAIN; RADIOGRAPHY; RISK FACTOR; COMPARATIVE STUDY; MESOTHELIOMA; METABOLISM; OCCUPATIONAL EXPOSURE; PATHOLOGY; RESPIRATORY TRACT TUMOR; SENSITIVITY AND SPECIFICITY; TURKEY (REPUBLIC);

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; OCCUPATIONAL EXPOSURE; RESPIRATORY TRACT NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TURKEY;

EID: 0036444604     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03032393     Document Type: Article

References (26)

1. Sheibani K, Battifora H, Burke JS: Antigenic phenotype of malignant mesothelioma and pulmonary adenocarcinomas. Am J Pathol 123: 212-219, 1986
2. Sosolik RC, Mcgaughy VR, De Young BR: Anti-MOC-31: A potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 10: 716-719, 1997
3. Donna A, Betta PG, Chiodera P, et al: Newly marketed tissue markers for malignant mesothelioma: Immunoreactivity of rabbit AMAD-2 antiserum, compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol 28: 929-937, 1997
4. Zeren EH, Gümürdülü D, Roggli VL, et al: Environmental Malignant Mesothelioma in Southern Anatolia: A study of fifty cases. Environ Health Perspect 108: 1047-1050, 2000
5. Warnock ML, Stoloff A, Thor A: Differentiation of adenocarcinoma of the lung from mesothelioma: Periodic acid schiff, monoklonal antibodies B 72.3 and leu MI. Am J Pathol 133: 30-38, 1988
6. Brown RW, Clark GM, Tandon AK, et al: Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 24: 347-354, 1993
7. Skov BG, Lauritzen AF, Hirsch F, et al: The histopathological diagnosis of malignant mesothelioma v.pulmonary adenocarcinoma: Reproducibility of the histopathological diagnosis. Histopathology 24: 553-557, 1994
8. Skov B, Lauritzen AF, Hirsch F, et al: Differantiation of adenocarcinoma of the lung and malignant mesothelioma: Predictive value and reproducibility of immunoreactive antibodies. Histopathology 25: 431-437, 1994
9. Wirth PR, Legier J, Wright GL: Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 67: 655-662, 1991
10. Zeng L, Feith J, Monnet I, et al: Immunocytochemical characterization of cell lines from human malignant mesothelioma: Characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Hum Pathol 25:3: 227-234, 1994
11. Cagle PT, Truong LD, Roggli VL, et al: Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms. Am J Clin Pathol 92: 566-571, 1989
12. Sheibani K, Esteban JM, Bailey A, et al: Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 23: 107-116, 1992
13. Bateman AC, Al-Talib RK, Newman T: Immunohistochemical phenotype of malignant mesothelioma: Predictive value of CA 125 and HBME-1 expression. Histopathology 30: 49-56, 1997
14. Dejmek A, Hjerpe A: Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis. APMIS 102: 255-264, 1994
15. Bartifora H, Kopinski MI: Distinction of mesothelioma from adenocarcinoma. Cancer 55: 1679-1685, 1985
16. Kortsik CS, Werner P, Freudenberg N, et al: Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3 - A new tumor marker. Lung 173: 79-87, 1995
17. Moch H, Oberholzer M, Dalquen P, et al: Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings. Virchows Arch A Pathol Anat 423: 19-27, 1993
18. Mezger J, Lamerz R, Permanetter W: Diagnostic significance of carcinoembryonic antigen in the differantial diagnosis of malignant mesothelioma. J Thorac Cardiovasc Surg 100: 860-866, 1990
19. Morgan RL, De Young BR, McGaughy VR, et al: MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 87: 390-394, 1999
20. Edwards C, Oates J: OV 632 and MOC-31 in the diagnosis of mesothelioma and adenocarcinoma: An assessment of their use in formalin fixed and paraffin wax embedded material. J Clin Pathol 48: 626-630, 1995
21. Ordonez NG: Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 29: 166-169, 1998
22. Attanoos RL, Goddard H, Gibbs AR: Mesothelioma-binding antibodies: Thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 29: 209-215, 1996
23. Kennedy AD, King G, Kerr KM: HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol 50: 859-862, 1997
24. Fetsch PA, Abati A, Hijazi YM: Utility of the antibodies CA 199, HBME-1 and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 84: 101-108, 1998
25. Riera JR, Astengo-Osuna C, Longmate JA, et al: The immunohistochemical diagnostic panel for epithelial mesothelioma: A reevaluation after heat induced epitope retrieval. Am J Surg Pathol 21: 1409-1419, 1997
26. Cury PM, Butcher DN, Fisher C, et al: Value of the rhesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 13: 107-112, 2000